Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Psychotic depression

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    179 result(s) found for: Psychotic depression. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2004-002156-34 Sponsor Protocol Number: 28133 Start Date*: 2005-06-14
    Sponsor Name:NV Organon
    Full Title: Double-blind, placebo-controlled trial investigating the safety of re-exposure to 900 mg of Org 34517, used as adjunctive therapy in subjects with psychotic major depression (major depressive episo...
    Medical condition: Psychotic major depression (major depressive episode, severe, with psychotic features)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10037250 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-000041-60 Sponsor Protocol Number: D1443L00040 Start Date*: 2008-06-17
    Sponsor Name:LWL Universitätsklinik für Psychiatrie Bochum
    Full Title: Quetiapine in the treatment of psychotic depression. A pilot study (QTP-Dep-Bo)
    Medical condition: The planned open and monocentric trial investigates quetiapine as a monotherapy for patients with unipolar depression and psychotic features. The aim of this pilot study is to investigate the antid...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012393 Depression psychotic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000050-23 Sponsor Protocol Number: 28130 Start Date*: 2004-09-15
    Sponsor Name:NV Organon
    Full Title: Prospective, double-blind, randomized, placebo-controlled dose finding study of the efficacy and safety of 2 target doses of Org 34517 used as adjunctive therapy in subjects with psychotic major de...
    Medical condition: Psychotic major depression (major depressive episode, severe, with psychotic features)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10037250 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001361-32 Sponsor Protocol Number: 14571A Start Date*: 2013-04-29
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study to evaluate the efficacy and safety of brexpiprazole (1 and 3 mg/day) as adjunctive treatment in el...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004873 10025461 Major depressive disorder, recurrent episode, severe degree, without mention of psychotic behavior LLT
    16.1 100000004873 10025462 Major depressive disorder, recurrent episode, unspecified degree LLT
    16.1 100000004873 10025457 Major depressive disorder, recurrent episode, mild degree LLT
    16.1 100000004873 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) LT (Prematurely Ended) FI (Prematurely Ended) SK (Prematurely Ended) EE (Prematurely Ended) BG (Prematurely Ended) GB (Prematurely Ended) PL (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001380-76 Sponsor Protocol Number: 14570A Start Date*: 2013-03-28
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose long-term study to evaluate the maintenance of efficacy and safety of 1 to 3 mg/day of brexpiprazole a...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004873 10025461 Major depressive disorder, recurrent episode, severe degree, without mention of psychotic behavior LLT
    18.0 100000004873 10025463 Major depressive disorder, single episode LLT
    18.0 100000004873 10025469 Major depressive disorder, single episode, severe degree, without mention of psychotic behavior LLT
    18.0 100000004873 10025462 Major depressive disorder, recurrent episode, unspecified degree LLT
    18.0 100000004873 10025467 Major depressive disorder, single episode, moderate degree LLT
    18.0 100000004873 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    18.0 100000004873 10025470 Major depressive disorder, single episode, unspecified degree LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) SE (Completed) FI (Completed) LT (Completed) GB (Completed) BG (Completed) IT (Prematurely Ended) LV (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-001618-34 Sponsor Protocol Number: 1208.24 Start Date*: 2006-12-11
    Sponsor Name:BOEHRINGER ING.
    Full Title: An eight-week, randomized, double-blind, two parallel groups, study to assess clinical response of Duloxetine 60 mg and 120 mg per day in patients hospitalized for severe depression
    Medical condition: Treatment of severely depressed patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012378 Depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-004647-37 Sponsor Protocol Number: G0373 Start Date*: 2006-11-06
    Sponsor Name:Bangor University
    Full Title: Folate Augmentation of Treatment – Evaluation of Depression: a randomised controlled trial
    Medical condition: Individuals with moderate to severe depression according to ICD-10 criteria.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012378 Depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004169-42 Sponsor Protocol Number: 14767B Start Date*: 2013-08-14
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, open-label, long-term extension study to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in patients with major depressive disorder.
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004873 10025461 Major depressive disorder, recurrent episode, severe degree, without mention of psychotic behavior LLT
    16.0 100000004873 10025463 Major depressive disorder, single episode LLT
    16.0 100000004873 10025469 Major depressive disorder, single episode, severe degree, without mention of psychotic behavior LLT
    16.0 100000004873 10025462 Major depressive disorder, recurrent episode, unspecified degree LLT
    16.0 100000004873 10025467 Major depressive disorder, single episode, moderate degree LLT
    16.0 100000004873 10025457 Major depressive disorder, recurrent episode, mild degree LLT
    16.0 100000004873 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    16.0 100000004873 10025470 Major depressive disorder, single episode, unspecified degree LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) LT (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) FI (Prematurely Ended) SK (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) LV (Prematurely Ended) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004049-19 Sponsor Protocol Number: NL77938.018.23 Start Date*: 2023-10-13
    Sponsor Name:Amsterdam UMC
    Full Title: Sodium oxybate as a potential new treatment for catatonia in patients with depression, bipolar disorder or a psychotic disorder, a randomized controlled trial. The Laborit study.
    Medical condition: Catatonia in patients with depression, bipolar disorder or a psychotic disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000952-17 Sponsor Protocol Number: NT13403 Start Date*: 2013-04-29
    Sponsor Name:Prague Psychiatric Centre
    Full Title: The Role of mTOR (Mammalian Target of Rapamycin) Signaling Pathway in the Antidepressive Effect of Ketamine in Patients with Depressive Disorder.
    Medical condition: 1. Men and women at the age between 18 to 65 years, with dextromanual dominance. 2. Patients have to answer DSM IV criteria for the major depressive episode, without psychotic symptoms, on the clin...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004030-28 Sponsor Protocol Number: EKFADHTC01032017 Start Date*: 2018-09-10
    Sponsor Name:Psychiatric Research Unit
    Full Title: Cognition and weight gain during antidepressant treatment.
    Medical condition: Major Depressive Disorder.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10012375 Depressed mood disorders and disturbances HLGT
    20.0 10037175 - Psychiatric disorders 10045543 Unipolar depression LLT
    20.0 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    20.0 10037175 - Psychiatric disorders 10025467 Major depressive disorder, single episode, moderate degree LLT
    20.0 10037175 - Psychiatric disorders 10025462 Major depressive disorder, recurrent episode, unspecified degree LLT
    20.0 10037175 - Psychiatric disorders 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    20.0 10037175 - Psychiatric disorders 10025463 Major depressive disorder, single episode LLT
    20.0 10037175 - Psychiatric disorders 10025454 Major depressive disorder, recurrent episode LLT
    20.0 10037175 - Psychiatric disorders 10025461 Major depressive disorder, recurrent episode, severe degree, without mention of psychotic behavior LLT
    20.0 10037175 - Psychiatric disorders 10025456 Major depressive disorder, recurrent episode, in partial or unspecified remission LLT
    20.0 10037175 - Psychiatric disorders 10067465 Major depressive disorder aggravated LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003658-47 Sponsor Protocol Number: F02207 GE 3 03 Start Date*: 2006-11-21
    Sponsor Name:Pierre Fabre Médicament - IRPF
    Full Title: Exploratory study of the efficacy and safety of flexible doses of Milnacipran and Venlafaxine administered in out patients with Major Depressive Disorder.
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012378 Depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-016715-38 Sponsor Protocol Number: TEAprotocolversion3-12102009FINAL Start Date*: 2010-02-08
    Sponsor Name:University of Copenhagen
    Full Title: The TEA Trial- Tolerance and Effect of Antipsychotics in children and adolescents with psychosis An investigator-initiated, phase IV, randomised double-blind multi-centre trial of the benefits and...
    Medical condition: non-organic and non-drug-induced psychosis, meeting the criteria for ICD-10 diagnoses: F20, F22-F29 and F30.2, F31.2, F31.5, F32.3 and F33.3.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10032314 Other nonorganic psychoses LLT
    16.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    16.1 10037175 - Psychiatric disorders 10004916 Bipolar affective disorder, depressed, severe degree, specified as with psychotic behavior LLT
    16.1 10037175 - Psychiatric disorders 10025460 Major depressive disorder, recurrent episode, severe degree, specified as with psychotic behaviour LLT
    16.1 10037175 - Psychiatric disorders 10039621 Schizoaffective disorder PT
    16.1 10037175 - Psychiatric disorders 10025468 Major depressive disorder, single episode, severe degree, specified as with psychotic behavior LLT
    16.1 10037175 - Psychiatric disorders 10046122 Unspecified psychosis LLT
    16.1 10037175 - Psychiatric disorders 10026780 Manic psychosis LLT
    16.1 10037175 - Psychiatric disorders 10012255 Delusional disorder, unspecified type PT
    16.1 10037175 - Psychiatric disorders 10051988 Acute and transient psychotic disorder LLT
    16.1 10037175 - Psychiatric disorders 10004924 Bipolar affective disorder, manic, severe degree, specified as with psychotic behavior LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007645-12 Sponsor Protocol Number: 250101 Start Date*: 2008-07-15
    Sponsor Name:University of York
    Full Title: The Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy (REEACT) Trial
    Medical condition: Depression
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002160-24 Sponsor Protocol Number: BP25712 Start Date*: 2012-04-12
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of RO4995819 Versus Placebo, as Adjunctive Therapy in Patients with Major D...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10012378 Depression PT
    14.1 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2018-004208-20 Sponsor Protocol Number: GH001-MDD-102 Start Date*: 2019-08-21
    Sponsor Name:Gh Research Limited
    Full Title: A phase 1/2 study of GH001 in patients with treatment-resistant depression
    Medical condition: Treatment-resistant depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    21.1 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-006879-42 Sponsor Protocol Number: GH001-PPD-203 Start Date*: 2022-08-30
    Sponsor Name:GH Research Ireland Limited
    Full Title: A phase 2 clinical trial of GH001 in patients with postpartum depression
    Medical condition: Post-Partum Depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10056393 Postpartum depression LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005457-25 Sponsor Protocol Number: PCN-101-21 Start Date*: 2021-08-30
    Sponsor Name:Perception Neuroscience, Inc
    Full Title: A randomized, placebo-controlled, double-blind study to assess the safety and efficacy of intravenous PCN-101 in treatment-resistant depression
    Medical condition: Treatment-resistant depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000520-14 Sponsor Protocol Number: NL46653 Start Date*: 2014-07-31
    Sponsor Name:University Medical Center Utrecht
    Full Title: Prednisolone addition for atients with recent onset psychotic disorder: the role of immune-modulating strategies in the treatment of psychosis.
    Medical condition: Schizophrenia, schizophreniphorm disorder, schizoaffective disorder, psychosis NOS.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003076-22 Sponsor Protocol Number: PSY-201401_ESPRIT Start Date*: 2016-07-07
    Sponsor Name:Central Institute of Mental Health Mannheim (ZI)
    Full Title: Multimodal Prevention of First Psychotic Episode – a 2x2-Factorial Randomized Trial investigating the efficacy of Acetylcysteine (ACC) and Integrated Preventive Psychological Intervention (IPPI) in...
    Medical condition: Clinical High Risk state for developing a first psychotic episode
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    20.0 10037175 - Psychiatric disorders 10061920 Psychotic disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 23:25:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA